Journal of Asthma, 21(6), 463-464 (1984)

# AUTHOR INDEX

# VOLUME 21


A

Abd El-Hafez, S.A., 259–263
Ago, Y., 151–159
Anton-Guirgis, H., 1–8

B

Bahna, S.L., 73–79
Baldwin, J.N., 299–303
Bennett, J., 443–450
Bizzini, B., 29–33

C

Cardoso, R.R. de A., 167–181
Chipps, B.E., 15–20
Chryssanthopoulos, C., 41–51
Cohen, B.M., 305–309
Creer, T.L., 9–13, 295–298
Cummiskey, J.M., 243–257

D

Daman, H.R., 331–337
Davies, R.J., 443– 450
DeCouto, J., 311–319
Dorow, P., 81–88

E

Edelman, L.J., 311–319
El-Khayat, H., 259–263
El-Shennawy, F.A., 259–263

F

Falliers, C.J., 271–272, 321–330, 371
Fanta, C.H., 387–405
Fink, J.N., 41–51
Fish, J.E., 407–418
Friedman, M.S., 97–117

G

Ghory, J.E., 273–274
Godfrey, S., 275–277
Green, L.D., 35–39

H

Hafez, M., 259–263
Harm, D.L., 9–13, 295–298
Helsel, C.L., 35–39
Henocq, E., 29–33
Hiehls, M.E., 35–39
Howard, M.L., 299–303
Huntley, W., 265–270

I

Ickovic, M.-R., 29–33
Imada, Y., 151–159

J

Jensen, B.K., 299–303
Jurenec, G.S., 21–28

K

Kaushik, S.P., 73–79
Kobayashi, R.H., 299–303
Kotses, H., 9–13, 295–298
Krikos, A., 209–213
Kuroume, T., 89–95

L

Leffert, F.H., 131–139
Levison, H., 239–241

M

Mak, H., 15–20
Mansmann, H.C., Jr., 35–39, 339–341
Marion, R.J., 295–298
Marquis, N.R., 311–319
McGeady, S.J., 35–39, 339–341
Mellits, E.D., 15–20
Menkes, H.A., 15–20
Mitsuhashi, M., 89–95
Morikawa, A., 89–95

N

Nagata, S., 151–159
Naspitz, C.K., 451–460

O

Osman, J., 443–450

P

Permutt, S., 15–20
Popa, V.T., 183–207, 243–257

R

Reilly, P.A., 239–241
Relyveld, E.H., 29–33
Rosner, F., 119–129

S

Saccar, C.L., 35–39
Sceptor, R.D., 343–345
Schanfield, M.S., 1–8
Scherr, M.S., 15–20
Schiess, W., 81–88
Schuberth, K.C., 15–20
Seever, D.D., 343–345
Shturman, R., 279–280
Solway, J., 419–426

T

Taijima, K., 89–95
Talamo, J.H., 15–20
Talamo, R.C., 15–20
Teshima, H., 151–159
Tinkelman, D.G., 311–319, 373, 461–462
Tokuyama, K., 89–95
Townley, R.G., 1–8, 427–442
Triggle, D.J., 375–385

U

Ullman, D.G., 21–28

W

Weinberger, M., 265–270
Weinstein, A.G., 161–165, 281–283

Z

Zedan, M., 259–263
Zoller, J.E., 53–57

Journal of Asthma, 21(6), 465-468 (1984)

# SUBJECT INDEX

# VOLUME 21


A

Acetylcholine, inhaled, bronchial reactivity to in young adults with history of childhood asthma, 151–159
Administration
  of adrenergic drugs, 199–200
  of theophylline, 251–252
β-Adrenergic agents, therapeutic effects of in asthma, 192–198
Adrenergic drugs, clinical pharmacology of, 183–207
Adults, with history of childhood asthma, atopic reactivity and bronchial reactivity to inhaled acetylcholine in, 151–159
Airway challenges, by calcium channel blocking agents
  in animals, 431–432
  in humans, 432–434
Airway obstruction. *See* Peak expiratory flow rate (PEFR)
Airway responsiveness, in asthmatics, influence of ketotifen on, 81–88
Allergens, identification of, 167–170
Allergic asthma, role of calcium channel blocking agents in, 427–442
Allergic bronchopulmonary aspergillosis, 41–51
Allergic factors, relationship of to panic-fear and emotional precipitants in childhood asthma, 21–28
Allergies
  cutaneous and mucosal diagnostic tests for, 167–181
  nasal and paranasal, 131–139
  upper respiratory, and lower respiratory disease, 137–139
  *See also* House dust mites
Allotypes, Gm, and methacholine inhalation in familial asthma, 1–8
Analgesic sensitivity, mechanisms of, 324–326
Antigens, of allergic bronchopulmonary aspergillosis, 42
Antipyretics, use of in childhood asthma, 321–330
Anxiety, role of in pediatric asthma death, 105–106
*Aspergillus*. *See* Allergic bronchopulmonary aspergillosis
Aspirin, use of in childhood asthma, 321–330
Atopic reactivity, to house dust mite in young adults with history of childhood asthma, 151–159

B

Basophils, effect of calcium channel blocking agents on, 428–431
Bioavailability
  of controlled-release theophylline formulation for once-daily use, 305–309
  of sustained-release theophylline, 35–39
Biochemical action, of theophyllines, 243–245
Biological markers. *See* Methacholine inhalation; Allotypes
Blocking agents, calcium channel, in bronchial hyperreactivity, 419–426
Bronchial hyperreactivity. *See* Hyperreactivity, bronchial
Bronchial reactivity, to inhaled acetylcholine in young adults with history of childhood asthma, 151–159
Bronchoconstriction, methacholine-induced, use of direct-writing recorder device in evaluation of, in childhood asthma, 89–95
Bronchodilation, with isoproterenol delivered from metered-dose inhaler, in children, 265–270
Bronchospasm. *See* Crying-induced bronchospasm (CIB)

C

Calcium, role of in airway smooth muscle contraction and mast cell secretion, 387–405

Calcium channel antagonists, 378–379, 407–418
Calcium channel blocking agents
in bronchial hyperreactivity, 419–426
inhaled, use of in treatment of asthma, 443–450
introduction to symposium on, 373
role of in treatment of allergic asthma, 427–442
use of in management of childhood asthma, 451–460
Calcium metabolism, cellular, 375–385
Calcium mobilization pathways, 376–378
Camps. *See* Summer camp
Childhood asthma
atopic disposition and bronchial reactivity to inhaled acetylcholine in young adults with history of, 151–159
crying-induced bronchospasm in, 161–165
personal account of, 53–57, 209–213
psychological factors associated with death in, 97–117
relationship between panic-fear, emotional precipitants, and allergic factors in, 21–28
treatment of in 1980s, 339–341
use of aspirin and antipyretics in, 321–330
use of calcium channel blocking agents in management of, 451–460
use of direct-writing recorder device in evaluation of methacholine-induced bronchoconstriction in, 89–95
water and electrolyte status in, 73–79
Children, bronchodilation in, with isoproterenol delivered from metered-dose inhaler, 265–270
CIB. *See* Crying-induced bronchospasm (CIB)
Clinical findings, relationship of to pharmacokinetics of theophylline, 311–319
Clinical manifestations, of allergic bronchopulmonary aspergillosis, 42–43
Clinical pharmacology, of adrenergic drugs, 183–207
Clinical studies, in children with calcium channel blocking agents, 454–457
Contraction, of airway smooth muscle, role of calcium in, 387–405
Controlled-release formulation, of theophylline, for once-daily use, serum profile and bioavailability of, 305–309
*Corynebacterium granulosum*, effect of immunostimulation with P40 derived from on patients with recurring respiratory infections, 29–33
Crying-induced bronchospasm (CIB), in childhood asthma, 161–165
Cutaneous diagnostic tests, for allergy, 170–174

D

Death, in childhood asthma, psychological factors associated with, 97–117
Demographic variables, in pediatric asthma death, 99–100
Diagnosis, of allergic bronchopulmonary aspergillosis, 48–49
Diagnostic tests, cutaneous and mucosal, for allergy, 167–181
Drugs, interaction of with adrenergic drugs, 200

E

Electrolyte status, in childhood asthma, 73–79
Emotional precipitants, of asthma attacks, relationship of to panic-fear and allergic factors in childhood asthma, 21–28
Emotional stress, role of in pediatric asthma death, 103–104
Epidemiology, of allergic bronchopulmonary aspergillosis, 41–42
Extrinsic bronchial asthma, HLA in, 259–263

F

Familial asthma, methacholine inhalation and Gm allotypes in, 1–8
Family dysfunction, in pediatric asthma death, 107–109
Fear. *See* Panic-Fear
Fluid therapy *See* Water status

H

Hand nebulizers, dependence on, role of in pediatric asthma death, 109-110
Hay fever. *See* Seasonal allergic rhinitis
High risk asthmatics, psychological models for identification of, 111–112
Histologic studies, of allergic bronchopulmonary aspergillosis, 46–47
HLA. *See* Human leucocyte antigen (HLA)
Home management, role of in pediatric asthma death, 109–110
House dust mites, atopic reactivity to, in young adults with history of childhood asthma, 151–159
Human leucocyte antigen (HLA), and extrinsic bronchial asthma, 259–263
Hyperreactivity, bronchial, calcium channel blocking agents in, 419–426

I

Immunomodulator. *See* P40
Immunopathogenic mechanisms, of allergic bronchopulmonary aspergillosis, 47–48
Immunostimulation, with P40 derived from *Corynebacterium granulosum*, effect of on patients with recurring respiratory infections, 29–33
Inhalation challenge studies, of allergic bronchopulmonary aspergillosis, 45–46
Inhaled calcium channel blocking agents. *See* Calcium channel blocking agents, inhaled

Inhaler, metered-dose, bronchodilation with isoproterenol delivered from, in children, 265–270
Intolerance to aspirin, in asthma, 321–324
Isoproterenol, delivered from metered-dose inhaler, bronchodilation in children with, 265–270

K

Ketotifen
  influence of on airway responsiveness in asthmatics, 81–88
  use of in management of childhood asthma, 454

L

Laboratory evaluation, of allergic bronchopulmonary aspergillosis, 43

M

Miamonides, Moses, treatise on asthma by, 119–129
Mast cells
  effect of calcium channel blocking agents on, 428–431
  secretion by, role of calcium in, 387–405
Mechanism of action
  of adrenergic drugs, 185–186
  of calcium channel blocking agents, 434–438
Medical factors, in pediatric asthma death, 100–102
Methacholine
  sensitivity to inhalation of, and Gm allotypes in familial asthma, 1–8
  use of direct-writing recorder device in evaluation of bronchoconstriction induced by, in childhood asthma, 89–95
Mucosal diagnostic tests, for allergy, 174–180

N

Nasal polyps, 135–136

O

Otis media, 137

P

P40, derived from *Corynebacterium granulosum*, effect of immunostimulation with on patients with recurring respiratory infections, 29–33
Panic-fear, relationship of to emotional precipitants and allergic factors in childhood asthma, 21–28
Peak expiratory flow rate (PEFR)
  intrasubject comparisons of using portable peak-flow meters, 9–13
  pulmonary function testing using, 331–337
Pediatric asthma. *See* Childhood asthma
Perennial rhinitis, 134–135
Personal account, of childhood asthma, 53–57, 209–213
Pharmacokinetics
  of adrenergic drugs, 186–192
  of theophylline, relationship of to clinical findings, 311–319
  of theophyllines, 245–251
Psychological factors
  in adult asthma death, 110–111
  in pediatric asthma death, 97–117
Pulmonary function
  of asthmatics at summer camp, effect of weather on, 15–20
  effect of subject effort on measurement of, 295–298
  testing of using peak expiratory flow rate, 331–337

R

Radiographic features, of allergic bronchopulmonary aspergillosis, 43–45
Recorder device, direct-writing, use of in evaluation of methacholine-induced bronchoconstriction, in childhood asthma, 89–95
Respiratory infections, recurring, effect of immunostimulation with P40 derived from *Corynebacterium granulosum* on patients with, 29–33

S

Seasonal allergic rhinitis, 133–134
Serum, theophylline levels in, in children receiving sustained-release theophylline tablet, 299–303
Serum profile, of controlled-release theophylline formulation for once-daily use, 305–309
Side effects, of adrenergic drugs, 198–199
Sinusitus, 136
Smooth muscle, airway, role of calcium in contraction of, 387–405
Sodium cromoglycate, use of in management of childhood asthma, 453–454
Spirometry. *See* Pulmonary function
Structure-activity relationship, of adrenergic drugs, 183–185
Subject effort, effect of on measurement of pulmonary function, 295–298
Summer camp, effect of weather on pulmonary function of asthmatics at, 15–20

Sustained-release theophylline. *See* Theophylline, sustained release preparations of, 35–39

T

Tablets, sustained-release theophylline, serum levels of in children receiving, 299–303
Theophylline
  controlled-release formulation of for once-daily use, serum profile and bioavailability of, 305–309
  pharmacokinetics of, relationship of to clinical findings, 311–319
  serum levels of in children receiving sustained-release tablets, 299–303
  sustained release preparations of, bioavailability studies of, 35–39
Theophyllines, review of, 243–257
Therapeutic uses, of calcium channel antagonists, 407–418
Therapy, for allergic bronchopulmonary aspergillosis, 49–50

V

Vitalograph pulmonary monitor. *See* Peak-flow meters

W

Water status, in childhood asthma, 73–79
Weather, effect of on pulmonary function of asthmatics at summer camp, 15–20
Wright peak-flow meter. *See* Peak-flow meters